FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes
The US Food and Drug Administration has approved ertugliflozin, a fourth SGLT2 inhibitor for use in adults with type 2 diabetes .Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Diabetes | Diabetes Type 2 | Endocrinology | Food and Drug Administration (FDA) | Health | SGLT2 Inhibitors